This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
UnitedHealth Group (UNH) Wins Medicaid Deal to Help Serve Texas
by Zacks Equity Research
UnitedHealth Group (UNH) unit has been awarded a contract by the Texas Health and Human Services Commission to better cater to the statewide Medicaid members.
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Select Medical (SEM) Up 18% Year to Date: More Room to Run?
by Zacks Equity Research
Select Medical (SEM) is well-poised for growth on the back of a credible healthcare facility portfolio built through buyouts and JVs coupled with strong cash-generating abilities.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Surgery Partners
by Zacks Equity Research
Medpace, HealthEquity and Surgery Partners are part of the Zacks Industry Outlook article.
Zacks.com featured highlights include Medpace, Invitation Home and Ryanair
by Zacks Equity Research
Medpace, Invitation Home and Ryanair are part of the Zacks Screen of the Week article.
3 Medical Services Stocks Countering Industry-Wide Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most. However, staffing shortages may disrupt the trend.
3 Top Stocks Exhibiting Superb Earnings Growth
by Tirthankar Chakraborty
Invest in stocks such as Medpace Holdings (MEDP), Invitation Home (INVH) and Ryanair Holdings (RYAAY) for solid earnings growth.
Acadia Healthcare (ACHC) Up 11% in 3 Months: More Room to Run?
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on an expansive healthcare portfolio, which in turn, boosts its patient volumes.
3 Reasons Growth Investors Will Love Medpace (MEDP)
by Zacks Equity Research
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Medpace (MEDP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Medpace (MEDP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Medpace (MEDP) have performed compared to their sector so far this year.
Medpace (MEDP) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 1.58% and 6.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Soars 21.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Apollo Medical
by Zacks Equity Research
Medpace, HealthEquity and Apollo Medical are part of the Zacks Industry Outlook article.
Brookdale (BKD) May 2023 Occupancy Rises: Better Days Ahead?
by Zacks Equity Research
Brookdale (BKD) has witnessed 19 straight months of year-over-year increases in weighted average occupancy level.
3 Medical Services Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and AMEH are set to gain the most. However, staffing shortages may disrupt the trend.
Humana (HUM) Arm Reaches 250 Senior Primary Care Facilities
by Zacks Equity Research
Humana's (HUM) CenterWell business focuses on providing a better healthcare experience through clubbing primary care, home health and pharmacy services.
Should You Retain Acadia Healthcare (ACHC) in Your Portfolio?
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is likely to receive support from growth in specialty treatment and acute inpatient psychiatric facilities.
Here's Why Investors Should Hold Encompass Health (EHC) Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth, attributable to expanding patient admissions, robust expansion endeavors and strong cash-generating abilities.